S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Mobile-based Simparo Surgical secures fourth patent for orthopedic tech

A Mobile-based medical device startup has secured its fourth U.S. patent, marking a significant step in the company's mission to streamline thumb CMC reconstruction. Supported by Innovate Alabama and Hatch Fairhope, the firm is now positioning its Falcon Suture Clutch as a localized alternative to traditional, complex surgical methods.

Mobile-based Simparo Surgical secures fourth patent for orthopedic tech
Photo: Bio & News

The newly patented technology, U.S. Patent No. 12,661,103, offers a solution to the mechanical hurdles inherent in basal joint reconstruction. Traditional surgical techniques often necessitate harvesting tendons from secondary sites and drilling bone tunnels, which complicates the procedure and increases recovery time. Simparo’s approach utilizes a one-way, suture-locking mechanism that allows surgeons to achieve precise, incremental tensioning during the operation.

CEO Chris Harber emphasized that the achievement reflects the broader growth of Alabama’s innovation ecosystem. By developing, protecting, and manufacturing its orthopedic portfolio within the state, the company aims to build a direct pipeline to local hand surgeons. With four patents now in its arsenal, Simparo is looking to scale its suture tensioning system into a wider family of orthopedic applications intended to simplify procedures while maintaining structural stability for patients.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!